Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Dermatologic 2Tumor-Agnostic 1Thoracic 1Gastrointestinal 1

Conditions

Leukemia 2Leukemia, Myeloid, Chronic-Phase 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × BMS-833923 × Other hematologic neoplasm × Clear all
NCT01357655 2017-03-14

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Bristol-Myers Squibb

Phase 2 Terminated
70 enrolled 8 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

NCT01218477 2016-06-17

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Bristol-Myers Squibb

Phase 1/2 Completed
33 enrolled 18 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡